Home > News > Dose-Dense Chemotherapy Plus Bevacizumab Followed by Nab-Paclitaxel Appears Cardiac Safe in Early-Stage Breast Cancer: Presented at SABCS
December 16th, 2008
Dose-Dense Chemotherapy Plus Bevacizumab Followed by Nab-Paclitaxel Appears Cardiac Safe in Early-Stage Breast Cancer: Presented at SABCS
Abstract:
A dose-dense anthracycline-based therapy that includes bevacizumab followed by nanoparticle albumin-bound paclitaxel (nab-paclitaxel) appears to avoid serious cardiac toxicity in its role as adjuvant treatment for early-stage breast cancer, researchers reported at the 31st Annual San Antonio Breast Cancer Symposium (SABCS).
Heather McArthur, MD, Memorial Sloan-Kettering Cancer Center, New York, New York and colleagues enrolled 80 women with early-stage breast cancer into a trial in which patients were treated with bevacizumab 10 mg/kg administered intravenously every 2 weeks for 8 cycles, concurrently with doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles, and then nab-paclitaxel 260 mg/m2 every 2 weeks for 4 cycles. After 8 cycles, for the rest of 1 year, bevacizumab was administered at a dose of 15 mg/kg every 3 weeks. Pegfilgrastim was administered on day 2 of each chemotherapy cycle.
Source:
docguide.com
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Events/Classes
A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||